$CETY

Clean Energy Technologies, Inc. (CETY): Entry into a Material Definitive Agreement

Clean Energy Technologies, Inc. (CETY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 3 ex10-2.htm EX-10.2 Exhibit 10.2 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFER

Original reporting
Published Jul 8, 2026, 9:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 8, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CETY
Neutral
medium confidence
Mentioned
$CETY
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CETYNeutralMed
01

Why it matters

Traders should reassess CETY’s near-term liquidity and potential equity issuance risk because the note features mandatory monthly payments, event-of-default triggers, and a mechanism to convert unpaid amounts into common stock.

02

Market read

New debt financing terms are disclosed, which can change perceived credit risk and dilution expectations for CETY.

03

What to watch

Key missing details for trading are the conversion terms (conversion price/ratio), whether proceeds were received at issuance, and the stated use of funds; these can swing dilution and credit-risk interpretation.

Relevance 6/10Novelty 7/10Timing: Filed after-hours on 2026-07-08, ahead of the next monthly payment schedule.

Background

The 8-K reports Item 1.01 (material definitive agreement) and Item 2.03 (direct financial obligation), with an exhibit describing a promissory note issued June 29, 2026.

Company-level read

Ticker impact

$CETYNeutralMedium confidence
Context

CETY entered a material definitive agreement issuing a $166.5k promissory note with 22% default interest and monthly payments through Aug 2026.

Expected impact

Moderate downside risk if investors view the note as expensive/credit-stressed, offset by potential cash runway if proceeds are used effectively.

Evidence & confidence

The filing is a primary disclosure of debt terms (principal, interest, payment schedule, default interest, and conversion mechanics). However, the excerpt does not state proceeds use, conversion ratio, or whether the note is already funded, limiting precision on equity impact.

Market effects

Adds another example of small-cap clean energy firms using structured debt with potential equity conversion, reinforcing sector financing sensitivity.

Primarily impacts US small-cap risk sentiment rather than a specific region.

Limited global spillover; relevant mainly to investors tracking US micro/small-cap capital structure risk.

Counterpoint

The note includes an acceleration/prepayment right and monthly amortization, which could reduce long-term default risk if CETY’s cash flow stabilizes.

Key entities

  • Clean Energy Technologies, Inc.

    Subject of the 8-K, borrower under the promissory note and party to the definitive agreement.

  • Coventry Enterprises LLC

    Holder/payee of the promissory note, receiving principal plus interest and having default remedies including conversion-related provisions.

Related articles

$ABTHigh

Abbott Plans to Separate Nutrition Business Into Publicly Traded Company by End of 2027

Abbott Laboratories (ABT) plans to spin off its Nutrition division, generating $8.5B in annual revenue, into a separate publicly traded company by the end of 2027. The move, subject to approvals, will allow Abbott to focus on medical devices, diagnostics, and pharmaceuticals, with the new company led by Daniel Salvadori. Existing shareholders will receive shares in both entities, and the transaction is not expected to affect Abbott's 2026 or 2027 financial guidance.

$ABTMed

Abbott Stock Falls 4% on Similac Spinoff: It’s Shedding Its Slowest Business, but Who Keeps the Lawsuits?

Abbott Laboratories (ABT) shares dropped 4% after announcing plans to spin off its Nutrition business, including Similac, by 2027. The unit generates $8.5B annually but has shown minimal growth. The move leaves Abbott with a medical device and diagnostics business, with $42B in annual sales. The company expects to maintain its 2026 guidance and current dividend payouts. Daniel Salvadori will lead the new nutrition company.

$UDRHigh

UDR, Apollo form $2B joint venture

UDR and Apollo are forming a $2B joint venture for 19 apartment properties. Apollo will invest $1.34B for a two-thirds stake, while UDR retains one-third and will manage the portfolio. UDR plans to use proceeds for high-growth assets, debt reduction, and corporate purposes. The transaction implies a 6% cap rate and is expected to close on Oct. 29.

$ABTHighAI 8/10

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company

ABBOTT LABORATORIES (ABT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company • Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies • The new Nutrition company will be a gl

$ABTMed

Abbott to Carve Out Nutrition Business Into Independent Company -- 2nd Update

Abbott Laboratories plans to separate its nutrition business, with $8.5B in annual sales, into an independent company by 2027. The move aims to focus on higher-growth areas. Shares fell 4% premarket. Q3 sales rose 14% to $13.01B, but profit declined due to higher costs. Abbott faces ongoing litigation over its baby-formula facility and has agreed to multimillion-dollar settlements.